NRC NRC HEALTH
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 70487 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.4%
TTM net income YoY-60.6%
TTM EPS YoY6,909.9%
Revenue 3-yr CAGR-1.1%
Net income 3-yr CAGR-39.3%
Margins
Gross margin—
Operating margin11.1%
Net margin4.5%
FCF margin12.8%
EBITDA margin17.0%
Returns
ROE248.1%
ROA4.7%
ROIC (approx.)10.9%
Asset turnover1.05x
Leverage & solvency
Liabilities / assets106.6%
Debt / equity—
Current ratio0.64x
Interest coverage2.91x
Cash quality & payout
Operating cash flow / net income3.69x
Accruals ratio-12.6%
Payout ratio209.2%
Capex / revenue3.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $38.40M | $35.39M | $34.80M | $35.19M | $34.61M | $34.04M | $33.55M | $36.91M |
| SG&A expense | $12.04M | $22.95M | $13.42M | $14.45M | $12.27M | $17.73M | $10.36M | $11.45M |
| Operating income | $8.91M | -$3.24M | $5.57M | $4.67M | $7.74M | $1.59M | $8.60M | $9.59M |
| Interest expense | $1.53M | $1.32M | $1.25M | $1.37M | $1.46M | $1.03M | $899,000 | $729,000 |
| Pretax income | $7.40M | -$4.54M | $4.38M | $3.27M | $6.27M | $581,000 | $7.72M | $8.88M |
| Income tax | $2.70M | -$1.25M | $1.16M | $1.47M | $2.15M | $687,000 | $1.94M | $2.31M |
| Net income | $4.70M | -$3.28M | $3.22M | $1.80M | $4.12M | -$106,000 | $5.79M | $6.56M |
| EBITDA | $10.98M | -$1.12M | $7.74M | $6.81M | $9.93M | $3.33M | $10.14M | $11.10M |
| EPS (basic) | 0.22 | -0.15 | 0.14 | — | 0.18 | -0.01 | 0.25 | — |
| EPS (diluted) | 0.21 | -0.15 | 0.14 | — | 0.18 | -0.01 | 0.25 | — |
| Dividends declared per share | 0.16 | 0.16 | 0.16 | 0.16 | 0.12 | 0.12 | 0.12 | 0.12 |
| Weighted avg. shares (diluted) | 21.89M | 22.01M | 21.91M | — | 22.13M | 22.66M | 22.97M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $3.63M | $3.33M | $2.55M | $4.14M | $2.22M | $5.27M | $2.50M | $4.23M |
| Receivables | $15.34M | $9.32M | $10.83M | $11.11M | $12.75M | $12.42M | $11.33M | $11.05M |
| Current assets | $26.71M | $22.81M | $19.98M | $20.21M | $20.40M | $25.32M | $20.40M | $19.60M |
| PP&E, net | $38.34M | $39.50M | $40.30M | $40.47M | $41.41M | $42.23M | $40.39M | $38.27M |
| Goodwill | $66.15M | $66.15M | $66.15M | $66.15M | $66.15M | $66.15M | $66.15M | $66.15M |
| Intangibles | $2.04M | $2.10M | $2.17M | $2.23M | $2.32M | $2.42M | $2.52M | $2.62M |
| Total assets | $139.21M | $136.15M | $134.56M | $134.88M | $135.72M | $141.39M | $135.18M | $132.54M |
| Current liabilities | $41.84M | $35.02M | $38.47M | $36.62M | $38.57M | $35.93M | $37.77M | $35.86M |
| Short-term debt | $4.77M | $4.02M | — | $4.01M | — | — | — | — |
| Long-term debt | $98.13M | $86.01M | $74.02M | $75.02M | $76.03M | $77.03M | $58.67M | $57.90M |
| Total debt | $102.90M | $90.03M | $74.02M | $79.03M | $76.03M | $77.03M | $58.67M | $57.90M |
| Total liabilities | $148.34M | $129.60M | $121.06M | $120.89M | $121.41M | $120.06M | $105.50M | $101.25M |
| Shareholders' equity | -$9.12M | $6.55M | $13.49M | $13.99M | $14.31M | $21.33M | $29.67M | $31.28M |
| Net debt | $99.27M | $86.70M | $71.47M | $74.90M | $73.81M | $71.75M | $56.17M | $53.66M |
| Shares outstanding | 21.22M | 22.14M | 22.54M | 22.64M | 22.66M | 23.10M | 22.79M | 23.08M |
| Cash flow statement | ||||||||
| Operating cash flow | $8.02M | $1.39M | $7.18M | $7.18M | $13.76M | -$1.14M | $6.65M | $6.38M |
| Capital expenditure | $1.04M | $1.32M | $1.83M | $1.12M | $3.59M | $3.01M | $2.99M | $4.44M |
| Free cash flow | $6.98M | $62,000 | $5.35M | $6.06M | $10.18M | -$4.15M | $3.66M | $1.94M |
| Investing cash flow | -$1.04M | -$1.32M | -$1.83M | -$1.12M | -$3.59M | -$3.01M | -$2.99M | -$4.44M |
| Financing cash flow | -$6.68M | $718,000 | -$6.94M | -$4.14M | -$13.23M | $6.92M | -$5.39M | -$1.16M |
| Depreciation & amortization | $2.07M | $2.12M | $2.17M | $2.15M | $2.19M | $1.74M | $1.54M | $1.52M |
| Stock-based compensation | -$135,000 | $7.37M | $1.61M | $1.91M | $925,000 | $307,000 | $171,000 | $188,000 |
| Dividends paid | $3.54M | $3.61M | $3.62M | $2.70M | $2.78M | $2.73M | $2.77M | $2.82M |
| Share buybacks | $15.98M | $7.64M | $1.94M | $1,000 | $9.27M | $5.99M | $4.92M | $7.40M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.